Cancellous bone formation response to simulated resistance training during disuse is blunted by concurrent alendronate treatment

J Bone Miner Res. 2011 Sep;26(9):2140-50. doi: 10.1002/jbmr.407.

Abstract

The purpose of this study was to assess the effectiveness of simulated resistance training (SRT) exercise combined with alendronate (ALEN) in mitigating or preventing disuse-associated losses in cancellous bone microarchitecture and formation. Sixty male Sprague-Dawley rats (6 months old) were randomly assigned to either cage control (CC), hind limb unloading (HU), HU plus either ALEN (HU + ALEN), SRT (HU + SRT), or a combination of ALEN and SRT (HU + SRT/ALEN) for 28 days. HU + SRT and HU + SRT/ALEN rats were anesthetized and subjected to muscle contractions once every 3 days during HU (four sets of five repetitions, 1000 ms isometric + 1000 ms eccentric). Additionally, HU + ALEN and HU + SRT/ALEN rats received 10 µg/kg of body weight of ALEN three times per week. HU reduced cancellous bone-formation rate (BFR) by 80%, with no effect of ALEN treatment (-85% versus CC). SRT during HU significantly increased cancellous BFR by 123% versus CC, whereas HU + SRT/ALEN inhibited the anabolic effect of SRT (-70% versus HU + SRT). SRT increased bone volume and trabecular thickness by 19% and 9%, respectively, compared with CC. Additionally, osteoid surface (OS/BS) was significantly greater in HU + SRT rats versus CC (+32%). Adding ALEN to SRT during HU reduced Oc.S/BS (-75%), Ob.S/BS (-72%), OS/BS (-61%), and serum TRACP5b (-36%) versus CC. SRT and ALEN each independently suppressed a nearly twofold increase in adipocyte number evidenced with HU and inhibited increases in osteocyte apoptosis. These results demonstrate the anabolic effect of a low volume of high-intensity muscle contractions during disuse and suggest that both bone resorption and bone formation are suppressed when SRT is combined with bisphosphonate treatment.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Acid Phosphatase / blood
  • Adipocytes / drug effects
  • Adipocytes / pathology
  • Alendronate / pharmacology*
  • Alendronate / therapeutic use*
  • Animals
  • Apoptosis / drug effects
  • Body Weight / drug effects
  • Bone and Bones / drug effects
  • Bone and Bones / pathology*
  • Bone and Bones / physiopathology
  • Cell Count
  • Hindlimb Suspension
  • Isoenzymes / blood
  • Male
  • Muscle Contraction / drug effects
  • Muscular Disorders, Atrophic / blood
  • Muscular Disorders, Atrophic / drug therapy*
  • Muscular Disorders, Atrophic / pathology
  • Muscular Disorders, Atrophic / physiopathology*
  • Organ Size / drug effects
  • Osteocytes / drug effects
  • Osteocytes / pathology
  • Osteogenesis / drug effects*
  • Rats
  • Rats, Sprague-Dawley
  • Resistance Training*
  • Tarsus, Animal / drug effects
  • Tarsus, Animal / pathology
  • Tarsus, Animal / physiopathology
  • Tartrate-Resistant Acid Phosphatase

Substances

  • Isoenzymes
  • Acid Phosphatase
  • Tartrate-Resistant Acid Phosphatase
  • Alendronate